Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: Identification of a second generation lead by a combinatorial chemistry approach

被引:82
作者
Smith, RA
Barbosa, J
Blum, CL
Bobko, MA
Caringal, YV
Dally, R
Johnson, JS
Katz, ME
Kennure, N
Kingery-Wood, J
Lee, W
Lowinger, TB
Lyons, J
Marsh, V
Rogers, DH
Swartz, S
Walling, T
Wild, H
机构
[1] Bayer AG, Res Ctr, Dept Chem Res, W Haven, CT 06516 USA
[2] Bayer AG, Res Ctr, Dept Canc Res, W Haven, CT 06516 USA
[3] Onyx Pharmaceut, Richmond, CA 94806 USA
关键词
D O I
10.1016/S0960-894X(01)00571-6
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Heterocyclic ureas, such as N-3-thienyl N'-aryl ureas, have been identified as novel inhibitors of raf kinase, a key mediator in the ras signal transduction pathway. Structure-activity relationships were established, and the potency of the screening hit was improved 10-fold to IC50 = 1.7 muM. A combinatorial synthesis approach enabled the identification of a breakthrough lead (IC50 = 0.54 muM) for a second generation series of heterocyclic urea raf kinase inhibitors. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2775 / 2778
页数:4
相关论文
共 16 条
  • [1] ANTEUNIS MJO, 1987, B SOC CHIM BELG, V96, P133
  • [2] ANTEUNIS MJO, 1987, B SOC CHIM BELG, V96, P119
  • [3] BOS JL, 1989, CANCER RES, V49, P4682
  • [4] 1-Phenyl-5-pyrazolyl ureas: Potent and selective p38 kinase inhibitors
    Dumas, J
    Hatoum-Mokdad, H
    Sibley, R
    Riedl, B
    Scott, WJ
    Monahan, MK
    Lowinger, TB
    Brennan, C
    Natero, R
    Turner, T
    Johnson, JS
    Schoenleber, R
    Bhargava, A
    Wilhelm, SM
    Housley, TJ
    Ranges, GE
    Shrikhande, A
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (18) : 2051 - 2054
  • [5] Discovery of a new class of p38 kinase inhibitors
    Dumas, J
    Sibley, R
    Riedl, B
    Monahan, MK
    Lee, W
    Lowinger, TB
    Redman, AM
    Johnson, JS
    Kingery-Wood, J
    Scott, WJ
    Smith, RA
    Bobko, M
    Schoenleber, R
    Ranges, GE
    Housley, TJ
    Bhargava, A
    Wilhelm, SM
    Shrikhande, A
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (18) : 2047 - 2050
  • [6] Protein kinase inhibitors: emerging pharmacophores 1997-2000
    Dumas, J
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (03) : 405 - 429
  • [7] DUMAS J, 1998, EXP OPIN THER PAT, V8, P1749
  • [8] The discovery of potent cRaf1 kinase inhibitors
    Lackey, K
    Cory, M
    Davis, R
    Frye, SV
    Harris, PA
    Hunter, RN
    Jung, DK
    McDonald, OB
    McNutt, RW
    Peel, MR
    Rutkowske, RD
    Veal, JM
    Wood, ER
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (03) : 223 - 226
  • [9] FUNCTION AND REGULATION OF RAS
    LOWY, DR
    WILLUMSEN, BM
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1993, 62 : 851 - 891
  • [10] RECONSTITUTION OF THE RAF-1-MEK-ERK SIGNAL-TRANSDUCTION PATHWAY IN-VITRO
    MACDONALD, SG
    CREWS, CM
    WU, L
    DRILLER, J
    CLARK, R
    ERIKSON, RL
    MCCORMICK, F
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (11) : 6615 - 6620